Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 10 von 478894

Details

Autor(en) / Beteiligte
Titel
Urological Cancer 2022
Ort / Verlag
Basel: MDPI - Multidisciplinary Digital Publishing Institute
Erscheinungsjahr
2023
Link zum Volltext
Quelle
Alma/SFX Local Collection
Beschreibungen/Notizen
  • In the urological sphere, the number of tumor malignancies caused by cancer is continuously growing in Western countries. Although this is mainly due to the contemporary increase in the life expectancy of people in these geographic areas, many other factors are also contributing to this growth. Urological cancer is a complex and varied disease which affects different organs and mainly affects the male population. In fact, in most statistics, kidney, prostate, and bladder cancer are regularly included in the top-ten list of the most frequent neoplasms in males. The female population, however, has also been increasingly affected by renal and bladder cancer in the last decade. From these facts, it is clear that urological cancer is a problem of major concern in developed societies. This Topic Issue of Cancers intends to shed some light on the complexity of this field and will consider all useful and appropriate contributions from scientists and clinicians in order to improve urological cancer knowledge for patients’ benefit.
Sprache
Englisch
Identifikatoren
ISBN: 9783036569697, 3036569685, 9783036569680, 3036569693
DOI: 10.3390/books978-3-0365-6969-7
Titel-ID: cdi_oapen_doabooks_98967
Format
Schlagworte
22Rv1, activin, androgen receptor axis, biomarker, bisphenol A, bisphenol S, bladder cancer, Book Industry Communication, cancer genome, CAPRA-S, carbon-ion radiotherapy, castration resistance, castration resistant, castration sensitive, Charlson comorbidity index, clear cell renal cell carcinoma, Clinical & internal medicine, CNTF, CNTFRα, Consolidated Framework for Implementation Research, diagnosis, Diseases & disorders, E-MTAB-1980, early survival, elderly patients, energy metabolism, ERK, everolimus, false-positive results, ferroptosis, follow-up care, general practice, Gleason grade, GLS2, high-risk prostate cancer, immunotherapy, indocyanine green, INHBA, INHBB, INHBC, life expectancy, LNCaP, male incontinence, Medicine, migration, MMP, multiparametric magnetic-resonance imaging, n/a, nephron sparing, neuroendocrine carcinoma, nivolumab, non-interventional study, Oncology, PARP inhibition, particle beam therapy, pazopanib, PET scan, precision targeting, primary diagnosis, primary health care, process evaluation, prognostic model, proliferation, prostate cancer, prostate cancer survivors, prostate-specific antigen, prostate-specific membrane antigen positron-emission tomography, PSA, PSMA, radiotherapy, real world-data, renal cell carcinoma, robot-assisted partial nephrectomy, robotic prostatectomy, STAT3, systematic review, systemic immune-inflammation index, TCGA, time on drug, transforming growth factor-β family, trial-eligibility, tumor, ureteral neoplasms, ureteroscopy, urinary bladder neoplasms

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX